Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
14 April 2021 | Story Dr Nitha Ramnath
Thought-leader series: corruption

2021 UFS Thought-Leader Webinar Series 

PRESENTS

a webinar on 

CORRUPTION IN SOUTH AFRICA: THE ENDEMIC PANDEMIC

As a public higher-education institution in South Africa with a responsibility to contribute to public discourse, the University of the Free State (UFS) will be presenting the webinar as part of the Free State Literature Festival’s online initiative, VrySpraak-digitaal. The aim of the webinar series is to discuss issues facing South Africa by engaging experts at the university and in South Africa. Some of the topics for 2021 include, among others, reimagining universities for student success; corruption; local elections, the state of business – particularly in the Free State. 

In 2020, the webinar series saw the successful participation of leading experts engaging on COVID-19 and the crisis facing the country socially, economically, and politically. This year, in lieu of the Free State Arts Festival, the UFS will present the webinar virtually over a period of five months. 

Second webinar presented on 4 May 2021

The second webinar for 2021 forms part of the UFS Thought-Leader Series, which is in its fourth year running. The scourge of corruption in South Africa has become endemic at all levels of the state and has rapidly accelerated the nation’s descent from a position of credibility that it once occupied during the era of Nelson Mandela. The economy is damaged; many state-owned enterprises are rendered dysfunctional, while self-enrichment by some political party cadres continues unabated at the peril of stark poverty and deepening inequality of the broader population. 
Are there grounds for optimism for South Africans who have been deeply wounded by the state of the nation? 

Date: Tuesday 4 May 2021
Topic:  Corruption in South Africa: the endemic pandemic 
Time: 12:30-14:00
RSVP: Alicia Pienaar, pienaaran1@ufs.ac.za by 2 May 2021 

Facilitator:

Rector and Vice-Chancellor, UFS

Panellists:

Director, Institute for Accountability in Southern Africa
Campaigning as Accountability Now 


Former Judge at the High Court, Cape Town

Deputy National Director of Public Prosecutions, National Prosecuting Authority

Dean: Faculty of Law, University of the Free State

Bios of speakers:

Adv Paul Hoffman
Advocate Paul Hoffman SC, a native of Johannesburg and a Wits graduate, practised law at the sidebar from 1975 to 1980 and at the Cape bar from 1980 to 2006. He took silk in 1995 and acted on the Cape bench at the invitation of three successive judge presidents. After retiring from the bar, he was founding director of the Centre for Constitutional Rights, and in 2009 co-founder of Accountability Now – both NGOs that promote constitutionalism. He is best known for his work on the irregularities in the arms deals, the unconstitutionality of the Hawks, and the bread cartel case in which a general class action was developed by the courts. He is the author of many articles and one book, Confronting the Corrupt, published by Tafelberg.

Judge Dennis Davis
Judge Dennis Davis is a retired judge in South Africa’s high court. He was educated at the Herzlia School and the Universities of Cape Town and Cambridge; and served as judge of the High Court, Cape Town (since 1998) and Judge President of the Competition Appeal Court (since February 2000). He is honorary professor at the Universities of Cape Town, the Western Cape, Wits, and is an extraordinary professor in the University of the Free State Centre for Human Rights. He is also Chair of the Davis Tax Committee and was one of the drafters of the Competition Act 1998 and the Companies Act 2008. He authored 11 books and held visiting professorial posts at the universities of Toronto, Melbourne, Harvard, Florida Brown, Georgetown and New York University. 


Adv Ouma Rabaji-Rasethaba
Advocate Ouma Rabaji-Rasethaba currently serves as the Deputy National Director of Public Prosecutions responsible for the Asset Forfeiture Unit (AFU) within the National Prosecuting Authority. She is the national co-ordinator of the anti-corruption strategic objective in the NPA (coordinating priorities for the Specialised Commercial Crime Unit, Investigating Directorate, and Asset Forfeiture Unit within the NPA). Adv Rabaji was admitted as an attorney in 1990, and later as an advocate of the High Court in 1996. She was previously Special Director of the AFU during its formative years, after which she joined the corporate sector in the area of governance and risk, followed by the bar, and practising as an advocate before re-joining the AFU in 2020.

Prof John Mubangizi
Prof John Mubangizi is Dean of the Faculty of Law at the University of the Free State. He has been full professor for more than 16 years. From 2005 to 2007, he served as Deputy Dean of the Faculty of Law at the University of KwaZulu-Natal (UKZN). After that, he served as Deputy Vice-Chancellor and Head of the College of Law and Management Studies at UKZN for 10 years. Rated as an established researcher by the National Research Foundation, Prof Mubangizi is widely published, with more than 70 publications to his name – most in SAPSE-accredited peer-reviewed journals – as well as a book titled The Protection of Human Rights in South Africa: A Legal and Practical Guide, which is used by scholars, practitioners, and students of human rights law in South Africa. He has also presented more than 40 academic papers at international conferences.  Prof Mubangizi is a member of the Academy of Science of South Africa (ASSAf) and has served as member and adviser to the ASSAf Council. He was also Chairperson of the Higher Education Quality Committee of South Africa and member of the Council on Higher Education. He also serves on various committees and in different ad hoc positions at institutional, national, and international levels.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept